ClinicalTrials.gg
CompletedNCT03631732BRAAVE 2020Updated Sep 5, 2021Results posted

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

A Phase 3 interventional study of B/F/TAF and NRTIs in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 82 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
496
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing their baseline regimen in HIV-1 infected, virologically suppressed African American participants.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Self-describes as Black, African American, or mixed race, including Black
  • Currently receiving an antiretrovirals (ARV) regimen other than FDC of B/F/TAF that consists of any two NRTIs + allowed 3rd agent for ≥ 6 months
  • Allowed 3rd agents include any FDA-approved INSTI, with the exception of bictegravir, any FDA-approved NNRTI with the exception of etravirine, protease inhibitors or the CCR5 antagonist, maraviroc
  • If the baseline 3rd agent is dolutegravir, dosing other than 50 mg once daily is excluded
  • Baseline regimens containing drugs or > 2 classes of ARVs are not permitted, with the exception of the pharmacologic enhancers cobicistat (taken with elvitegravir or a PI), or ritonavir (taken with a PI)
  • Have no documented or suspected resistance to INSTIs and no history of virologic failure on an INSTI containing regimen (2 consecutive -1 RNA ≥ 50 copies/mL after achieving \<50 copies/mL while on an INSTI-containing regimen)
  • History of 1-2 thymidine analogue mutations (TAMs), M184V/I, and any other RT substitutions are allowed, with the following exceptions: History of 3 or more TAMs (M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/N/R), T69-insertions, or K65R/E/N in RT will be excluded
  • Documented plasma HIV-1 RNA \< 50 copies/mL during treatment with the baseline regimen for a minimum period of 6 months and at least the last two HIV-1 RNA measurements prior to the Screening visit
  • HIV-1 RNA levels \< 50 copies/mL at Screening
  • Estimated (eGFR) ≥ 50 mL/min according to the formula for creatinine clearance

Key Exclusion Criteria:

  • History of 3 or more TAMs (M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/N/R),T69-insertions, or K65R/E/N in RT
  • No desire to switch from current ARVs
  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening
  • Participants experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, or variceal bleeding)
  • Have been treated with therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic during the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
  • within 5 years of screening other than cutaneous Kaposi's sarcoma, completely resected non -melanoma skin cancer (basal cell carcinoma or non-invasive cutaneous squamous carcinoma), or completely resected carcinoma in-situ of the cervix (CIN 3) or anus (AIN 3). A prior malignancy treated with curative therapy and for which there has been no evidence of disease for at least five years prior to screening is allowed
  • Current alcohol or substance use judged by the Investigator to potentially interfere with participant study compliance
  • Active, serious infections (other than HIV-1 infection) requiring antibiotic or antifungal therapy within 30 days prior to Day 1
  • Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the dosing requirements
  • Known to FDC of B/F/TAF tablets, their metabolites, or formulation
  • Females who are pregnant (as confirmed by positive serum pregnancy test)
  • Females who are breastfeeding
  • Acute hepatitis in the 30 days prior to randomization
  • Active tuberculosis infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
496 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.

    Drug: B/F/TAF

  • Active comparator
    Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF

    Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.

    Drug: B/F/TAF · Drug: NRTIs · Drug: Third Agent

Interventions

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg FDC tablets administered orally once daily without regard to food

    Also known as: Biktarvy®

  • DrugNRTIs

    The following NRTIs will be administered as prescribed until Week 24 without regard to food: abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)

  • DrugThird Agent

    Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. : * Non-nucleoside reverse transcriptase inhibitors (NNRTIs) * delavirdine (DLV) * efavirenz (EFV) * nevirapine (NVP) * rilpivirine (RPV) * doravirine (DOR) * Integrase inhibitors * dolutegravir (DTG) * elvitegravir (EVG) * raltegravir (RAL) * Protease inhibitors (PIs) * atazanavir (ATV) * darunavir (DRV) * lopinavir (LPV) * nelfinavir NFV) * saquinavir (SQV) * tipranavir (TPV) * Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

    The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

    The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.

    Time frame: Week 48

  2. Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

    The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  3. Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set

    The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  4. Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

    The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.

    Time frame: Week 48

  5. Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set

    The analysis includes values up to 1 day after permanent discontinuation of study treatment.

    Time frame: Baseline to Week 24

  6. Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set

    The analysis includes values up to 1 day after permanent discontinuation of study treatment.

    Time frame: Baseline to Week 24

  7. Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set

    The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.

    Time frame: Baseline to Week 48

  8. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.

    Time frame: First B/F/TAF dose date up to Week 72 plus 30 days

  9. Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.

    Time frame: First B/F/TAF dose date up to Week 72 plus 30 days

07

Results

Posted Aug 27, 2020

Participant flow

Participants were enrolled at study centers in the United States. The first participant was screened on 28 August 2018. The last study visit occurred on 19 August 2020.

Randomized Phase Up to Week 24
Participant flow — Randomized Phase Up to Week 24
MilestoneB/F/TAFStay on Baseline Regimen (SBR)/ Delayed B/F/TAF
Started331165
Completed324163
Not completed72
Withdrew: Lost to follow-up30
Withdrew: Withdrew consent12
Withdrew: Adverse event20
Withdrew: Randomized but not treated10
B/F/TAF Treatment Phase (After Week 24)
Participant flow — B/F/TAF Treatment Phase (After Week 24)
MilestoneB/F/TAFStay on Baseline Regimen (SBR)/ Delayed B/F/TAF
Started319163
Completed303158
Not completed165
Withdrew: Lost to follow-up61
Withdrew: Withdrew consent33
Withdrew: Adverse event41
Withdrew: Death10
Withdrew: Investigator's discretion10
Withdrew: Lack of efficacy10

Outcome measures

PrimaryPercentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
percentage of participantsB/F/TAFStay on Baseline Regimen (SBR)
Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set0.6 (0.1 to 2.2)1.8 (0.4 to 5.2)
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · Difference in percentages: -1.2 · 95% CI -4.8 to 0.9Differences in percentages of participants with HIV-1 RNA \>= 50 copies/mL between treatment groups and 95% CI were calculated based on exact method.
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · Fisher Exact · p = 0.3399
SecondaryPercentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
percentage of participantsB/F/TAFDelayed B/F/TAF
Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set0.9 (0.2 to 2.6)0 (0.0 to 2.2)
SecondaryPercentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
percentage of participantsB/F/TAFStay on Baseline Regimen (SBR)
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set96.3 (93.7 to 98.1)94.5 (89.9 to 97.5)
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · Difference in percentages: 1.8 · 95% CI -2.0 to 6.8Differences in percentages of participants with HIV-1 RNA \< 50 copies/mL between treatment groups and 95% CI were calculated based on exact method.
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · Fisher Exact · p = 0.3532
SecondaryPercentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set

The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set
percentage of participantsB/F/TAFStay on Baseline Regimen (SBR)
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set99.3 (97.7 to 99.9)98.0 (94.2 to 99.6)
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · Difference in percentages: 1.4 · 95% CI -1.0 to 5.3Differences in percentages of participants with HIV-1 RNA \< 50 copies/mL between treatment groups and 95% CI were calculated based on exact method.
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · Fisher Exact · p = 0.3356
SecondaryPercentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set

The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
percentage of participantsB/F/TAFDelayed B/F/TAF
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set94.5 (91.5 to 96.7)96.9 (93.0 to 99.0)
SecondaryChange From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set

The analysis includes values up to 1 day after permanent discontinuation of study treatment.

Time frame:
Baseline to Week 24
Reported as:
Mean · cells/uL
Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set
cells/uLB/F/TAFStay on Baseline Regimen (SBR)
Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set13 ± 209.31 ± 171.2
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · ANOVA · p = 0.5618 · Difference in lsm: 11 · 95% CI -27 to 49Difference in LSM (Least square mean) and its 95% C.I. was calculated from ANOVA model with treatment as a fixed effect.
SecondaryChange From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set

The analysis includes values up to 1 day after permanent discontinuation of study treatment.

Time frame:
Baseline to Week 24
Reported as:
Mean · cells/uL
Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set
cells/uLB/F/TAFStay on Baseline Regimen (SBR)
Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set13 ± 210.14 ± 171.3
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen (SBR) · ANOVA · p = 0.6632 · Difference in lsm: 9 · 95% CI -31 to 48Difference in LSM and its 95% C.I. was calculated from ANOVA model with treatment as a fixed effect.
SecondaryChange From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set

The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.

Time frame:
Baseline to Week 48
Reported as:
Mean · cells/uL
Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set
cells/uLB/F/TAFDelayed B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set7 ± 188.6-8 ± 159.2
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.

Time frame:
First B/F/TAF dose date up to Week 72 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
percentage of participantsB/F/TAFDelayed B/F/TAF
Percentage of Participants Experiencing Treatment-Emergent Adverse Events83.369.3
SecondaryPercentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.

Time frame:
First B/F/TAF dose date up to Week 72 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities
percentage of participantsB/F/TAFDelayed B/F/TAF
Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities87.880.4

Adverse events

Collected over Adverse Events: First B/F/TAF dose date up to Week 72 plus 30 days. All-Cause Mortality: Randomization up to Week 72 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF up to Week 241/331 (0.3%)13/330 (3.9%)38/330 (11.5%)
SBR up to Week 240/165 (0%)7/165 (4.2%)13/165 (7.9%)
B/F/TAF After Week 242/319 (0.6%)20/319 (6.3%)53/319 (16.6%)
Delayed B/F/TAF0/163 (0%)7/163 (4.3%)26/163 (16%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventB/F/TAF up to Week 24SBR up to Week 24B/F/TAF After Week 24Delayed B/F/TAF
Covid-19Infections and infestations0/3300/1653/3190/163
Chest painGeneral disorders0/3300/1652/3190/163
Acute myocardial infarctionCardiac disorders0/3300/1651/3191/163
Gastric stenosisGastrointestinal disorders0/3300/1650/3191/163
Complication associated with deviceGeneral disorders0/3300/1650/3191/163
CellulitisInfections and infestations0/3300/1650/3191/163
HyperglycaemiaMetabolism and nutrition disorders0/3300/1650/3191/163
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3300/1650/3191/163
Lacunar infarctionNervous system disorders0/3300/1650/3191/163
Bipolar I disorderPsychiatric disorders0/3300/1650/3191/163
Most frequent other events
Most frequent other events
EventB/F/TAF up to Week 24SBR up to Week 24B/F/TAF After Week 24Delayed B/F/TAF
Upper respiratory tract infectionInfections and infestations20/3306/16517/31910/163
SyphilisInfections and infestations4/3301/16518/3197/163
DiarrhoeaGastrointestinal disorders11/3305/1654/3199/163
Pain in extremityMusculoskeletal and connective tissue disorders5/3302/16516/3196/163

Baseline characteristics

The Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1).

Age, Continuous
Age, Continuous(years)B/F/TAFStay on Baseline Regimen/ Delayed B/F/TAFTotal
Mean47 ± 12.348 ± 12.247 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFStay on Baseline Regimen/ Delayed B/F/TAFTotal
Female10155156
Male229110339
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B/F/TAFStay on Baseline Regimen/ Delayed B/F/TAFTotal
Hispanic or Latino15520
Not Hispanic or Latino315160475
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFStay on Baseline Regimen/ Delayed B/F/TAFTotal
American Indian or Alaska Native000
Asian000
Black or African American285154439
Native Hawaiian or Pacific Islander000
White000
Other451156
HIV-1 RNA Category
HIV-1 RNA Category(Participants)B/F/TAFStay on Baseline Regimen/ Delayed B/F/TAFTotal
< 50 copies/mL325163488
≥ 50 copies/mL527
CD4+ Cell Count
CD4+ Cell Count(cells/µL)B/F/TAFStay on Baseline Regimen/ Delayed B/F/TAFTotal
Mean765 ± 313.4757 ± 323.0763 ± 316.3
08

Study locations

82 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Alabama Medical Group, PC
    Mobile, Alabama 36608, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Mills Clinical Research
    Los Angeles, California 90069, United States
  • Highland Hospital- Alameda Health System
    Oakland, California 94602, United States
  • Kaiser Permanente
    Oakland, California 94611, United States
  • One Community Health
    Sacramento, California 95811, United States
  • Kaiser Permanente
    Sacramento, California 95825, United States
  • Kaiser Permanente, Department of Infectious Diseases
    San Leandro, California 94577, United States
  • Whitman-Walker Health
    Washington, District of Columbia 20005, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Washington Health Institute
    Washington, District of Columbia 20017, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • The GW Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Gary J. Richmond, M.D., P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • AIDS Healthcare Foundation - South Beach
    Miami Beach, Florida 33140, United States
  • AHF- The Kinder Medical Group
    Miami, Florida 33133, United States
  • University of Miami School of Medicine Division of Infectious Disease
    Miami, Florida 33136, United States
  • Orlando Immunology Center
    Orlando, Florida 32803-1851, United States
  • St. Joseph's Hospital Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research & Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33407, United States
  • Emory Hospital Midtown Infectious Disease Clinic
    Atlanta, Georgia 30308, United States
  • Atlanta ID Group, PC
    Atlanta, Georgia 30309, United States
  • Augusta University Medical Center
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialist of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University, Department of Internal Medicine
    Macon, Georgia 31201, United States
  • Chatham County Health Department
    Savannah, Georgia 31401, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • NorthStar Medical Center
    Chicago, Illinois 60657, United States
  • Indiana CTSI Clinical Research Center
    Indianapolis, Indiana 46077, United States
  • University Medical Center- New Orleans (UMCNO)
    New Orleans, Louisiana 70112, United States
  • SLVHCS Building J, 7th floor, Outpatient Infectious Disease Clinic
    New Orleans, Louisiana 70119, United States
  • CrescentCare Health
    New Orleans, Louisiana 70130, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • Claudia T. Martorell, MD, LLC d/b/a The Research Institute
    Springfield, Massachusetts 01105, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Wayne State University- Integrative Bioscience Center
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • St. John Newland Medical Associates
    Southfield, Michigan 48075, United States
  • Hennepin County Medical Center, Positive Care Clinic
    Minneapolis, Minnesota 55414, United States
  • G.V. 'Sonny' Montgomery VAMC
    Jackson, Mississippi 39216, United States
  • Southampton Clinical Research
    Saint Louis, Missouri 63108, United States
  • Clinical: Saint Louis University, New Hope Clinic
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • Huntridge Family Clinic
    Las Vegas, Nevada 89104, United States
  • Prime Healthcare Services- St. Michael's LLC d/b/a Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • North Shore University Hospital/Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • UT Physicians
    Charlotte, North Carolina 28207, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • East Carolina University, The Brody School of Medicine, ECU Adult Specialty Care
    Greenville, North Carolina 27834, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • AHF
    Pensacola, North Carolina 32504, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19066, United States
  • Philadelphia FIGHT Community Health Centers
    Philadelphia, Pennsylvania 19107, United States
  • Palmetto Health Richland
    Columbia, South Carolina 29203, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • St. Hope Foundation
    Bellaire, Texas 77401, United States
  • AIDS Arms, Inc. DBA Prism Health North Texas
    Dallas, Texas 75208, United States
  • North Texas Infectious Diseases Consultants, P.A.
    Dallas, Texas 75246, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Thomas Street Health Center
    Houston, Texas 77030, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • The Crofoot Research Center, INC (dba Gordon E. Crofoot MD PA)
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Community Health Care, Hilltop Medical Clinic
    Tacoma, Washington 98405, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Andreatta K, D'Antoni ML, Chang S, Parvangada A, Martin R, Blair C, et al. Preexisting Resistance and Week 48 Virologic Outcomes after Switching to B/F/TAF in African American Adults With HIV [Presentation]. IDWeek Virtual; 2020b 21-25 October.
  • Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopol M, McDonald C, Blair C, Andreatta K, Collins SE, Brainard D, Martin H. Week-48 Outcomes From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in African-American Adults With HIV, IDWeek 2020, October 21-25. Abstract 1046.
  • Andreatta K, D'Antoni ML, Chang S, Martin R, Blair C, Collins SE, et al. Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans [Poster 509]. Conference on Retroviruses and Opportunistic Infections (CROI); 2020b 08-11 March; Boston, MA.
  • Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopol M, McDonald C, Blair C, Andreatta K, Collins SE, Brainard D, Martin H. Randomized Switch to B/F/TAF in African American Adults with HIV. Conference on Retroviruses and Opportunistic Infections 2020, March 7-11, Boston MA. Abstract 2979.
  • Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopal MN, McDonald C, Blair C, Andreatta K, Collins SE, Brainard DM, Martin H; BRAAVE2020 Investigators. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):86-95. doi: 10.1097/QAI.0000000000002731. PubMed 34397746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Aug 2019, 11 months.

Results were first posted in Aug 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2018
First posted
Aug 15, 2018
StartActual
Aug 28, 2018
Primary completionActual
Aug 12, 2019
CompletionActual
Aug 19, 2020
Results first posted
Aug 27, 2020
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03631732
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 15, 2018
Start date
Aug 28, 2018
Primary completion
Aug 12, 2019
Completion
Aug 19, 2020
Results posted
Aug 27, 2020
Last update
Sep 5, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion